Peter J Little,, Bpharm

List of Publications by Year
in descending order

215 papers	8,714 citations	44042 48 h-index	66879 78 g-index
216 all docs	216 docs citations	216 times ranked	9449 citing authors

#	Article	IF	Citations
1	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacological Reviews, 2021, 73, 924-967.	7.1	359
2	FOXO Signaling Pathways as Therapeutic Targets in Cancer. International Journal of Biological Sciences, 2017, 13, 815-827.	2.6	338
3	Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis, 2012, 220, 3-10.	0.4	295
4	Insulin Resistance and Atherosclerosis. Endocrine Reviews, 2006, 27, 242-259.	8.9	275
5	LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cellular and Molecular Life Sciences, 2013, 70, 2859-2872.	2.4	229
6	Transforming growth factor-Î² signalling: Role and consequences of Smad linker region phosphorylation. Cellular Signalling, 2013, 25, 2017-2024.	1.7	216
7	Zinc and cardiovascular disease. Nutrition, 2010, 26, 1050-1057.	1.1	170
8	Proteoglycans Synthesized by Arterial Smooth Muscle Cells in the Presence of Transforming Growth Factor-Î²1 Exhibit Increased Binding to LDLs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 55-60.	1.1	148
9	Effect of moderate alcohol upon obstructive sleep apnoea. European Respiratory Journal, 2000, 16, 909-913.	3.1	125
10	Endothelin-1 signalling in vascular smooth muscle: Pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis, 2008, 199, 237-247.	0.4	123
11	Targeting Mechanosensitive Transcription Factors in Atherosclerosis. Trends in Pharmacological Sciences, 2019, 40, 253-266.	4.0	123
12	Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. , 2019, 196, 15-43.		110
13	The possible role of the Akt signaling pathway in schizophrenia. Brain Research, 2012, 1470, 145-158.	1.1	106
14	Naringenin and naringin in cardiovascular disease prevention: A preclinical review. European Journal of Pharmacology, 2020, 887, 173535.	1.7	103
15	Impact of Sleep Apnea on Sympathetic Nervous System Activity in Heart Failure. Chest, 2003, 123, 1119-1126.	0.4	101
16	Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-Î³ Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation. Circulation, 2003, 107, 2548-2550.	1.6	94
17	Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen. Medicinal Research Reviews, 2018, 38, 201-228.	5.0	90
18	SIRT6 protects against endothelial dysfunction and atherosclerosis in mice. Aging, 2016, 8, 1064-1082.	1.4	88

#	Article	IF	Citations
19	Plasma noradrenaline kinetics in humans. Journal of the Autonomic Nervous System, 1984, 11, 125-144.	1.9	87
20	Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential. Pharmacological Research, 2019, 139, 62-75.	3.1	85
21	Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Current Opinion in Lipidology, 2008, 19, 448-454.	1.2	84
22	TGF-Î² stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. Cellular and Molecular Life Sciences, 2010, 67, 2077-2090.	2.4	84
23	Endothelial function and dysfunction: Impact of metformin. , 2018, 192, 150-162.		82
24	Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride-sensitive Na(+)- and HCO3(-)-dependent mechanism.. Circulation Research, 1990, 67, 814-825.	2.0	80
25	The pH of spontaneously beating cultured rat heart cells is regulated by an ATP-calmodulin-dependent Na+/H+ antiport.. Circulation Research, 1989, 64, 676-685.	2.0	78
26	Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-Î°B activation. Translational Research, 2012, 160, 114-124.	2.2	78
27	Poly(ADPâ€ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications. Medicinal Research Reviews, 2014, 34, 644-675.	5.0	77
28	Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. Journal of Lipid Research, 2014, 55, 201-213.	2.0	77
29	Genetic and physiological association of diabetes susceptibility with raised Na+/H+ exchange activity.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5898-5902.	3.3	76
30	Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in Apolipoprotein-E knockout mice fed a high cholesterol diet. Archives of Biochemistry and Biophysics, 2011, 515, 72-79.	1.4	76
31	Thrombin Stimulation of Proteoglycan Synthesis in Vascular Smooth Muscle Is Mediated by Protease-activated Receptor-1 Transactivation of the Transforming Growth Factor Î² Type I Receptor. Journal of Biological Chemistry, 2010, 285, 26798-26805.	1.6	70
32	Angiotensin II and noradrenaline increase PDGF-BB receptors and potentiate PDGF-BB stimulated DNA synthesis in vascular smooth muscle. Biochemical and Biophysical Research Communications, 1990, 166, 580-588.	1.0	68
33	Novel iron oxideâ€“cerium oxide coreâ€“shell nanoparticles as a potential theranostic material for ROS related inflammatory diseases. Journal of Materials Chemistry B, 2018, 6, 4937-4951.	2.9	67
34	Targeting LOXâ€1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Annals of the New York Academy of Sciences, 2019, 1443, 34-53.	1.8	67
35	The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma. BioMed Research International, 2014, 2014, 1-10.	0.9	64
36	Diabetes-Induced Vascular Hypertrophy Is Accompanied by Activation of Na ⁺ -H ⁺ Exchange and Prevented by Na ⁺ -H ⁺ Exchange Inhibition. Circulation Research, 2000, 87, 1133-1140.	2.0	63

#	Article	IF	Citations
37	Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis, 2002, 162, 119-129.	0.4	63
38	Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. , 2011, 131, 255-268.		63
39	Hydrogels as artificial matrices for cell seeding in microfluidic devices. RSC Advances, 2020, 10, 43682-43703.	1.7	62
40	Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding <i>in vitro</i> and aortic lipid deposition <i>in vivo</i>. Journal of Cellular and Molecular Medicine, 2010, 14, 1408-1418.	1.6	61
41	Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cellular and Molecular Life Sciences, 2011, 68, 97-107.	2.4	61
42	Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics, 2021, 11, 4502-4515.	4.6	61
43	Metformin, Macrophage Dysfunction and Atherosclerosis. Frontiers in Immunology, 2021, 12, 682853.	2.2	59
44	Polyhalogenated biphenyls and phenobarbital: Evaluation as inducers of drug metabolizing enzymes in the sheepshead, Archosargus probatocephalus. Chemico-Biological Interactions, 1981, 36, 229-248.	1.7	58
45	Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships. Journal of Medicinal Chemistry, 1982, 25, 887-892.	2.9	58
46	Smad and p38 MAP Kinase-mediated Signaling of Proteoglycan Synthesis in Vascular Smooth Muscle. Journal of Biological Chemistry, 2008, 283, 7844-7852.	1.6	58
47	Treatment of atherosclerotic plaque: perspectives on theranostics. Journal of Pharmacy and Pharmacology, 2019, 71, 1029-1043.	1.2	56
48	Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease. Cardiovascular Research, 2007, 76, 19-28.	1.8	55
49	REGULATION AND ROLE OF UROKINASE PLASMINOGEN ACTIVATOR IN VASCULAR REMODELLING. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 759-765.	0.9	54
50	Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, GÃŽÂ±/q,11. Frontiers in Cardiovascular Medicine, 2015, 2, 14.	1.1	53
51	Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	53
52	Endothelin-1 Stimulation of Proteoglycan Synthesis in Vascular Smooth Muscle is Mediated by Endothelin Receptor Transactivation of the Transforming Growth Factor-Î² Type I Receptor. Journal of Cardiovascular Pharmacology, 2010, 56, 360-368.	0.8	52
53	PDGF Î²-Receptor Kinase Activity and ERK1/2 Mediate Glycosaminoglycan Elongation on Biglycan and Increases Binding to LDL. Endocrinology, 2010, 151, 4356-4367.	1.4	52
54	Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. Thrombosis Research, 2008, 123, 288-297.	0.8	51

#	Article	IF	Citations
55	Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. Biomedicine and Pharmacotherapy, 2017, 89, 1242-1251.	2.5	51
56	Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Theranostics, 2018, 8, 3007-3021.	4.6	51
57	Forkhead box O transcription factors as possible mediators in the development of major depression. Neuropharmacology, 2015, 99, 527-537.	2.0	50
58	Transforming growth factorâ€Î² regulation of proteoglycan synthesis in vascular smooth muscle: Contribution to lipid binding and accelerated atherosclerosis in diabetes. Journal of Diabetes, 2010, 2, 233-242.	0.8	49
59	Poly(aspartic acid) in Biomedical Applications: From Polymerization, Modification, Properties, Degradation, and Biocompatibility to Applications. ACS Biomaterials Science and Engineering, 2021, 7, 2083-2105.	2.6	49
60	Thrombin-mediated Proteoglycan Synthesis Utilizes Both Protein-tyrosine Kinase and Serine/Threonine Kinase Receptor Transactivation in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2013, 288, 7410-7419.	1.6	47
61	Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis. Nanoscale, 2018, 10, 15103-15115.	2.8	46
62	Leu143 in the Putative Fourth Membrane Spanning Domain Is Critical for Amiloride Inhibition of an Epithelial Na+/H+ Exchanger Isoform (NHE-2). Biochemical and Biophysical Research Communications, 1993, 193, 532-539.	1.0	45
63	Endothelin-1 and endothelin-3 stimulate calcium mobilization by different mechanisms in vascular smooth muscle. Biochemical and Biophysical Research Communications, 1992, 183, 694-700.	1.0	44
64	Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 601-613.	1.1	44
65	Gaq proteins: molecular pharmacology and therapeutic potential. Cellular and Molecular Life Sciences, 2017, 74, 1379-1390.	2.4	43
66	Inhibitors of hepatic mixed function oxidasesâ€"II Some benzimidazole, benzoxazole and benzothiazole derivatives. Biochemical Pharmacology, 1976, 25, 2747-2750.	2.0	42
67	Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacologica Sinica, 2022, 43, 2173-2190.	2.8	42
68	Total Synthesis of the Cyclic Depsipeptide YM-280193, a Platelet Aggregation Inhibitor. Organic Letters, 2015, 17, 492-495.	2.4	41
69	IGF-1 Signaling via the PI3K/Akt Pathway Confers Neuroprotection in Human Retinal Pigment Epithelial Cells Exposed to Sodium Nitroprusside Insult. Journal of Molecular Neuroscience, 2015, 55, 931-940.	1.1	41
70	The role of specific Smad linker region phosphorylation in TGF-Î² mediated expression of glycosaminoglycan synthesizing enzymes in vascular smooth muscle. Cellular Signalling, 2016, 28, 956-966.	1.7	41
71	Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. Journal of Lipid Research, 2002, 43, 149-157.	2.0	41
72	Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. Journal of Diabetes and Its Complications, 2001, 15, 120-127.	1.2	39

#	Article	IF	Citations
73	Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis. Current Vascular Pharmacology, 2008, 6, 195-203.	0.8	39
74	Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factorâ€like domain. FEBS Letters, 1997, 414, 471-474.	1.3	38
75	Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease. , 2019, 204, 107404.		38
76	Biosynthesis of Natural and Hyperelongated Chondroitin Sulfate Glycosaminoglycans: New Insights into an Elusive Process. The Open Biochemistry Journal, 2008, 2, 135-142.	0.3	38
77	Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vascular Health and Risk Management, 2007, 3, 117-24.	1.0	38
78	The expansion of GPCR transactivation-dependent signalling to include serine/threonine kinase receptors represents a new cell signalling frontier. Cellular and Molecular Life Sciences, 2015, 72, 799-808.	2.4	37
79	Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship. Biomedicines, 2021, 9, 699.	1.4	37
80	Troglitazone Stimulates Repair of the Endothelium and Inhibits Neointimal Formation in Denuded Rat Aorta. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 762-768.	1.1	36
81	Protease activated receptor-1 mediated dual kinase receptor transactivation stimulates the expression of glycosaminoglycan synthesizing genes. Cellular Signalling, 2016, 28, 110-119.	1.7	36
82	Hydrogels Based on Poly(aspartic acid): Synthesis and Applications. Frontiers in Chemistry, 2019, 7, 755.	1.8	36
83	Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function. Frontiers in Pharmacology, 2020, 11, 635.	1.6	36
84	Temperature-dependent disposition of [14C]benzo(a)pyrene in the spiny lobster, Panulirus argus. Toxicology and Applied Pharmacology, 1985, 77, 325-333.	1.3	35
85	(<i>S</i>)-[6]-Gingerol inhibits TGF-Î²-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells. Journal of Pharmacy and Pharmacology, 2013, 65, 1026-1036.	1.2	35
86	The Atypical Antipsychotic Agent, Clozapine, Protects Against Corticosterone-Induced Death of PC12 Cells by Regulating the Akt/FoxO3a Signaling Pathway. Molecular Neurobiology, 2017, 54, 3395-3406.	1.9	35
87	Non-invasive imaging techniques for the differentiation of acute and chronic thrombosis. Thrombosis Research, 2019, 177, 161-171.	0.8	35
88	Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-Î² signalling. Cellular and Molecular Life Sciences, 2020, 77, 243-251.	2.4	34
89	The emerging role of metformin in gestational diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 765-772.	2.2	33
90	Transforming growth factorâ€“Î²1 mediated CHST11 and CHSY1 mRNA expression is ROS dependent in vascular smooth muscle cells. Journal of Cell Communication and Signaling, 2019, 13, 225-233.	1.8	33

#	ARTICLE	IF	CITATIONS
91	The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction. Signal Transduction and Targeted Therapy, 2021, 6, 266.	7.1	33
92	VASCULAR LOCALIZATION OF THE 11?-HYDROXYSTEROID DEHYDROGENASE TYPE II ENZYME. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 549-551.	0.9	32
93	Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. Journal of Diabetes and Its Complications, 2007, 21, 108-117.	1.2	32
94	Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics, 2021, 11, 9376-9396.	4.6	32
95	Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. Journal of Lipid Research, 2002, 43, 149-57.	2.0	32
96	Cell biology of Smad2/3 linker region phosphorylation in vascular smooth muscle. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 661-667.	0.9	31
97	Cellular and Molecular Pathology of Age-Related Macular Degeneration: Potential Role for Proteoglycans. Journal of Ophthalmology, 2016, 2016, 1-7.	0.6	31
98	Characterization of intracellular translocation of Forkhead transcription factor O (FoxO) members induced by NGF in PC12 cells. Neuroscience Letters, 2011, 498, 31-36.	1.0	30
99	Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL. Atherosclerosis, 2009, 205, 451-457.	0.4	29
100	Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells. Biomedicine and Pharmacotherapy, 2016, 84, 1538-1550.	2.5	29
101	Role of Corticotropin Releasing Factor in the Neuroimmune Mechanisms of Depression: Examination of Current Pharmaceutical and Herbal Therapies. Frontiers in Cellular Neuroscience, 2019, 13, 290.	1.8	29
102	Androgens Stimulate Human Vascular Smooth Muscle Cell Proteoglycan Biosynthesis and Increase Lipoprotein Binding. Endocrinology, 2005, 146, 2085-2090.	1.4	28
103	The Paradigm of G Protein Receptor Transactivation: A Mechanistic Definition and Novel Example. Scientific World Journal, The, 2011, 11, 709-714.	0.8	28
104	G protein coupled receptor transactivation: Extending the paradigm to include serine/threonine kinase receptors. International Journal of Biochemistry and Cell Biology, 2012, 44, 722-727.	1.2	28
105	Forkhead family transcription factor FoxO and neural differentiation. Neurogenetics, 2012, 13, 105-113.	0.7	28
106	Amiodarone-Induced Retinal Neuronal Cell Apoptosis Attenuated by IGF-1 via Counter Regulation of the PI3k/Akt/FoxO3a Pathway. Molecular Neurobiology, 2017, 54, 6931-6943.	1.9	28
107	Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats. Journal of Medicinal Chemistry, 1982, 25, 622-626.	2.9	27
108	Determination of dose enhancement caused by gold-nanoparticles irradiated with proton, X-rays (kV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	27

#	Article	IF	Citations
109	The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease. ACS Pharmacology and Translational Science, 2020, 3, 457-471.	2.5	27
110	Desensitization of the alpha1 adrenoceptor system in vascular smooth muscle. Biochemical Pharmacology, 1984, 33, 1143-1145.	2.0	26
111	Platelet-derived Growth Factor Differentially Regulates the Expression and Post-translational Modification of Versican by Arterial Smooth Muscle Cells through Distinct Protein Kinase C and Extracellular Signal-regulated Kinase Pathways. Journal of Biological Chemistry, 2010, 285, 6987-6995.	1.6	26
112	Lithium ions attenuate serum-deprivation-induced apoptosis in PC12 cells through regulation of the Akt/FoxO1 signaling pathways. Psychopharmacology, 2016, 233, 785-794.	1.5	26
113	Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: Implications for lipoprotein binding and atherosclerosis. , 2018, 187, 88-97.		26
114	Flavopiridol Inhibits TGF-<i>Î²</i>-Stimulated Biglycan Synthesis by Blocking Linker Region Phosphorylation and Nuclear Translocation of Smad2. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 156-164.	1.3	26
115	The role of FOXOs and autophagy in cancer and metastasisâ€"Implications in therapeutic development. Medicinal Research Reviews, 2020, 40, 2089-2113.	5.0	26
116	Mechanical strain stimulates a mitogenic response in coronary vascular smooth muscle cells via release of basic fibroblast growth factor. American Journal of Hypertension, 2001, 14, 1128-1134.	1.0	25
117	Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans. Cardiovascular Pathology, 2013, 22, 146-155.	0.7	25
118	Transforming growth factor Î²-mediated site-specific Smad linker region phosphorylation in vascular endothelial cells. Journal of Pharmacy and Pharmacology, 2014, 66, 1722-1733.	1.2	25
119	Amiloride analogues cause endotheliumâ€dependent relaxation in the canine coronary artery <i>in vitro</i>: possible role of Na⁺/Ca²⁺ exchange. British Journal of Pharmacology, 1988, 95, 67-76.	2.7	24
120	Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors. Journal of Pharmacy and Pharmacology, 2013, 65, 465-473.	1.2	24
121	Thrombin promotes PAI-1 expression and migration in keratinocytes via ERK dependent Smad linker region phosphorylation. Cellular Signalling, 2018, 47, 37-43.	1.7	23
122	TGF-Î² stimulates biglycan core protein synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation in vascular smooth muscle. Growth Factors, 2011, 29, 203-210.	0.5	22
123	Insulin-like growth factor-1 induces the phosphorylation of PRAS40 via the PI3K/Akt signaling pathway in PC12 cells. Neuroscience Letters, 2012, 516, 105-109.	1.0	21
124	Nerve growth factor protects retinal ganglion cells against injury induced by retinal ischemiaâ€"reperfusion in rats. Growth Factors, 2015, 33, 149-159.	0.5	21
125	Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors. Journal of Cell Communication and Signaling, 2017, 11, 117-125.	1.8	21
126	Emodin in atherosclerosis prevention: Pharmacological actions and therapeutic potential. European Journal of Pharmacology, 2021, 890, 173617.	1.7	21

#	ARTICLE	IF	CITATIONS
127	Peptidylâ€prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 117-124.	0.9	20
128	Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways. International Journal of Molecular Sciences, 2018, 19, 2719.	1.8	20
129	Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes. Cellular Signalling, 2019, 53, 365-373.	1.7	20
130	Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. Biochemistry and Cell Biology, 1998, 76, 751-759.	0.9	19
131	Growth factor-mediated hyper-elongation of glycosaminoglycan chains on biglycan requires transcription and translation. Archives of Physiology and Biochemistry, 2009, 115, 147-154.	1.0	19
132	GPCR responses in vascular smooth muscle can occur predominantly through dual transactivation of kinase receptors and not classical GÎ±q protein signalling pathways. Life Sciences, 2013, 92, 951-956.	2.0	19
133	Protection of Neuronal Uptake-1 Inhibitors in Ischemic and Anoxic Hearts by Norepinephrine-Dependent and -Independent Mechanisms. Journal of Cardiovascular Pharmacology, 1998, 32, 621-628.	0.8	19
134	MECHANISMS INVOLVED IN THE STIMULATION OF ALDOSTERONE PRODUCTION BY ANGIOTENSIN II, VASOPRESSIN AND ENDOTHELIN. Clinical and Experimental Pharmacology and Physiology, 1990, 17, 263-267.	0.9	18
135	Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. Kidney International, 2005, 68, 2756-2765.	2.6	18
136	The status of radioimmunotherapy in CD20+ non-Hodgkinâ€™s lymphoma. Targeted Oncology, 2015, 10, 15-26.	1.7	18
137	Endothelin-1 (ET-1) stimulates carboxy terminal Smad2 phosphorylation in vascular endothelial cells by a mechanism dependent on ET receptors and <i>de novo</i> protein synthesis. Journal of Pharmacy and Pharmacology, 2016, 69, 66-72.	1.2	18
138	ROS directly activates transforming growth factor Î² type 1 receptor signalling in human vascular smooth muscle cells. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129463.	1.1	18
139	G protein coupled receptors can transduce signals through carboxy terminal and linker region phosphorylation of Smad transcription factors. Life Sciences, 2018, 199, 10-15.	2.0	17
140	Mechanisms of PAR-1 mediated kinase receptor transactivation: Smad linker region phosphorylation. Journal of Cell Communication and Signaling, 2019, 13, 539-548.	1.8	17
141	High glucose abolishes the antiproliferative effect of 17Î²-estradiol in human vascular smooth muscle cells. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E746-E751.	1.8	16
142	High glucose potentiates mitogenic responses of cultured ovine coronary smooth muscle cells to platelet derived growth factor and transforming growth factor-Î²1. Diabetes Research and Clinical Practice, 2003, 59, 93-101.	1.1	16
143	Glucosamine inhibits the synthesis of glycosaminoglycan chains on vascular smooth muscle cell proteoglycans by depletion of ATP. Archives of Physiology and Biochemistry, 2008, 114, 120-126.	1.0	15
144	Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes. Scientific World Journal, The, 2009, 9, 224-228.	0.8	15

#	Article	IF	Citations
145	Characterisation of Ki11502 as a potent inhibitor of PDGF Î² receptor-mediated proteoglycan synthesis in vascular smooth muscle cells. European Journal of Pharmacology, 2010, 626, 186-192.	1.7	15
146	Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells. Journal of Pharmacy and Pharmacology, 2013, 65, 1055-1063.	1.2	15
147	Smad2 linker region phosphorylation is an autonomous cell signalling pathway: Implications for multiple disease pathologies. Biomedicine and Pharmacotherapy, 2020, 124, 109854.	2.5	15
148	Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. Cardiovascular Diabetology, 2007, 6, 33.	2.7	14
149	Role of brain-derived neurotrophic factor and nerve growth factor in the regulation of Neuropeptide W inÂvitro and inÂvivo. Molecular and Cellular Endocrinology, 2017, 447, 71-78.	1.6	14
150	RNA sequencing to determine the contribution of kinase receptor transactivation to G protein coupled receptor signalling in vascular smooth muscle cells. PLoS ONE, 2017, 12, e0180842.	1.1	14
151	Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGFÎ² receptor phosphorylation. Archives of Biochemistry and Biophysics, 2012, 525, 25-31.	1.4	13
152	Changing environment of hyperglycemia in pregnancy: Gestational diabetes and diabetes mellitus in pregnancy. Journal of Diabetes, 2018, 10, 633-640.	0.8	13
153	Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates the mRNA expression of proteoglycan synthesizing genes XYLT1 and CHST3. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118848.	1.9	13
154	Curcumin Inhibits Lysophosphatidic Acid Mediated MCP-1 Expression via Blocking ROCK Signalling. Molecules, 2021, 26, 2320.	1.7	13
155	GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species. Vascular Biology (Bristol, England), 2019, 1, R1-R11.	1.2	13
156	Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis. Vascular Health and Risk Management, 2005, 1, 199-208.	1.0	13
157	3-Methylcholanthrene does not induce in vitro xenobiotic metabolism in spiny lobster hepatopancreas, or affect in vivo disposition of benzo[a]pyrene. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1984, 78, 241-245.	0.2	12
158	Dihydropyridine Ca2+ channel antagonists inhibit the salvage pathway for DNA synthesis in human vascular smooth muscle cells. European Journal of Pharmacology, 1993, 244, 269-275.	2.7	12
159	Platelet-derived growth factor-stimulated versican synthesis but not glycosaminoglycan elongation in vascular smooth muscle is mediated via Akt phosphorylation. Cellular Signalling, 2014, 26, 912-916.	1.7	12
160	Integrating the GPCR transactivationâ€dependent and biased signalling paradigms in the context of PAR1 signalling. British Journal of Pharmacology, 2016, 173, 2992-3000.	2.7	12
161	IGF-1-Mediated Survival from Induced Death of Human Primary Cultured Retinal Pigment Epithelial Cells Is Mediated by an Akt-Dependent Signaling Pathway. Molecular Neurobiology, 2018, 55, 1915-1927.	1.9	12
162	Toll-like Receptor 4 Stimulates Gene Expression via Smad2 Linker Region Phosphorylation in Vascular Smooth Muscle Cells. ACS Pharmacology and Translational Science, 2020, 3, 524-534.	2.5	12

#	ARTICLE	IF	CITATIONS
163	Role of Ca 2+ in Metabolic Inhibitionâ€“Induced Norepinephrine Release in Rat Brain Synaptosomes. Circulation Research, 1997, 80, 179-188.	2.0	12
164	Imidazole derivatives as inhibitors of cytochrome P-450-dependent oxidation and activators of epoxide hydrolase in hepatic microsomes from a marine fish. Biochemical Pharmacology, 1981, 30, 2876-2880.	2.0	11
165	Rapid regulation of adrenomedullin in metabolically compromised vascular smooth muscle cells. Journal of Hypertension, 1999, 17, 373-379.	0.3	11
166	p38 MAP Kinase Mediated Proteoglycan Synthesis as a Target for the Prevention of Atherosclerosis. Cardiovascular & Hematological Disorders Drug Targets, 2008, 8, 287-292.	0.2	11
167	Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes. Biochemistry and Cell Biology, 1998, 76, 751-759.	0.9	11
168	Primary â€œBrown Pigmentâ€•Bile Duct Stones. HPB Surgery, 1991, 4, 209-222.	2.2	10
169	Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle. Cardiovascular Diabetology, 2014, 13, 80.	2.7	10
170	Phosphorylated Troglitazone Activates PPARÎ³ and Inhibits Vascular Smooth Muscle Cell Proliferation and Proteoglycan Synthesis. Journal of Cardiovascular Pharmacology, 2008, 51, 274-279.	0.8	9
171	Stereoselective Reduction of 1â€<i>O</i>â€Isopropyloxygenipin Enhances Its Neuroprotective Activity in Neuronal Cells from Apoptosis Induced by Sodium Nitroprusside. ChemMedChem, 2014, 9, 1397-1401.	1.6	9
172	Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries. Diabetes Research and Clinical Practice, 2005, 70, 201-208.	1.1	8
173	Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response. Journal of Pharmacy and Pharmacology, 2016, 68, 368-378.	1.2	8
174	Endothelin-1 increases CHSY-1 expression in aortic endothelial cells via transactivation of transforming growth factor Î² type I receptor induced by type B receptor endothelin-1. Journal of Pharmacy and Pharmacology, 2019, 71, 988-995.	1.2	8
175	Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE-/- mice. Pharmacological Research, 2022, 175, 106043.	3.1	8
176	Inhibitors of hepatic mixed function oxidasesâ€”V. Inhibition of aminopyrine N-demethylation and enhancement of aniline hydroxylation by benzoxazole derivatives. Biochemical Pharmacology, 1982, 31, 1795-1798.	2.0	6
177	REGULATION OF SODIUM INFLUX AND SODIUM, POTASSIUM PUMP ACTIVITY BY A SODIUM-HYDROGEN ANTIPORT IN RAT VASCULAR SMOOTH MUSCLE. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 191-195.	0.9	6
178	Circulating digoxin-like immunoreactivity in renal hypertensive rabbits: lack of modulation by alterations in dietary sodium intake. Journal of Hypertension, 1988, 6, 205-209.	0.3	6
179	MULTIPLE GROWTH ABNORMALITIES IN VASCULAR SMOOTH MUSCLE FROM SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 319-322.	0.9	6
180	Pyrido-Pyrimidine Derivative CYC10424 Inhibits Glycosaminoglycan Changes on Vascular Smooth Muscle-derived Proteoglycans and Reduces Lipoprotein Binding. Journal of Cardiovascular Pharmacology, 2008, 52, 403-412.	0.8	6

#	ARTICLE	IF	CITATIONS
181	Akt acts as a switch for GPCR transactivation of the TGFâ€Î² receptor type 1. FEBS Journal, 2022, 289, 2642-2656.	2.2	6
182	The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells. Archives of Physiology and Biochemistry, 2008, 114, 171-177.	1.0	5
183	Factors affecting proteoglycan synthesis and structure that modify the interaction with lipoproteins. Clinical Lipidology, 2009, 4, 479-494.	0.4	5
184	Corrigendum to: Cardiovascular actions and therapeutic potential of tanshinone IIA [Atherosclerosis 220 (2012) 3â€"10]. Atherosclerosis, 2012, 221, 604.	0.4	5
185	<scp>S</scp>iah2â€deficient mice show impaired skin wound repair. Wound Repair and Regeneration, 2013, 21, 437-447.	1.5	5
186	Endothelin-1 mediated glycosaminoglycan synthesizing gene expression involves NOX-dependent transactivation of the transforming growth factor-Î² receptor. Molecular and Cellular Biochemistry, 2022, 477, 981-988.	1.4	5
187	Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-Î² receptor in vascular smooth muscle cells. Cellular and Molecular Life Sciences, 2022, 79, 121.	2.4	5
188	Effects of Alterations in Cell Phenotype and Hypokalemia on Sodium-Potassium Pump Activity in Rabbit Vascular Smooth Muscle. Clinical and Experimental Hypertension, 1985, 7, 1563-1582.	0.3	4
189	SPONTANEOUS OSCILLATIONS IN CYTOPLASMIC FREE CALCIUM CONCENTRATION IN VASCULAR SMOOTH MUSCLE: A POTENTIAL MECHANISM ASSOCIATED WITH MYOGENIC TONE. Clinical and Experimental Pharmacology and Physiology, 1988, 15, 281-284.	0.9	4
190	SODIUM-DEPENDENT, ETHYLISOPROPYLAMILORIDE-SENSITIVE MECHANISMS REGULATE INTRACELLULAR pH IN HUMAN VASCULAR SMOOTH MUSCLE. Clinical and Experimental Pharmacology and Physiology, 1990, 17, 297-301.	0.9	4
191	IONIC MECHANISMS REGULATING SODIUM ENTRY INTO VASCULAR SMOOTH MUSCLE. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 117-120.	0.9	4
192	Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands. Current Cardiology Reviews, 2005, 1, 89-102.	0.6	4
193	Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes. Current Diabetes Reviews, 2006, 2, 227-239.	0.6	4
194	Multiple Growth Factors, But Not VEGF, Stimulate Glycosaminoglycan Hyperelongation in Retinal Choroidal Endothelial Cells. International Journal of Biological Sciences, 2016, 12, 1041-1051.	2.6	4
195	Forkhead box protein O3 suppresses uveal melanoma development by increasing the expression of Bclâ€‘2â€‘like protein 11 and cyclinâ€‘dependent kinase inhibitor 1B. Molecular Medicine Reports, 2017, 17, 3109-3114.	1.1	4
196	New Approaches to Regulating the Chondroitin/Dermatan Sulfate Glycosaminoglycan Component of the Vascular Extracellular Matrix. Scientific World Journal, The, 2005, 5, 515-520.	0.8	3
197	Glutamate Attenuates the Survival Property of IGFR through NR2B Containing N-Methyl-D-aspartate Receptors in Cortical Neurons. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	1.9	3
198	Androgens: New Effects on Proteoglycan Biosynthesis and Its Consequences for Atherosclerosis. Scientific World Journal, The, 2005, 5, 521-526.	0.8	2

#	Article	IF	Citations
199	Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2020, 532, 239-243.	1.0	2
200	Vernolide-A and Vernodaline: Sesquiterpene Lactones with Cytotoxicity against Cancer. Journal of Environmental Pathology, Toxicology and Oncology, 2020, 39, 299-308.	0.6	2
201	Endothelinâ€1 dependent expression of <scp>GAG</scp> genes involves <scp>NOX</scp> and p38 mediated Smad linker region phosphorylation. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 710-718.	0.9	2
202	Another piece of cell biology in the puzzle of inflammation, glucose and diabetic vascular disease. Journal of Hypertension, 2008, 26, 396-398.	0.3	1
203	Methotrexate Inhibits Proliferation but not Proteoglycan Synthesis or Glycosaminoglycan Hyperelongation in Human Vascular Smooth Muscle Cells. Clinical & Experimental Pharmacology, 2015, 05, .	0.3	1
204	An Investigation of Sodium Fusidate and Recombinant Cytochrome P450 Enzymes Inhibition In-Vitro. Drug Metabolism Letters, 2016, 10, 180-186.	0.5	1
205	YYâ€11, a camel milkâ€derived peptide, inhibits TGFâ€Î²â€mediated atherogenic signaling in human vascular smooth muscle cells. Journal of Food Biochemistry, 2022, 46, e13882.	1.2	1
206	Role of Na-H Exchanger in Vascular Remodelling in Diabetes. , 2003, , 159-175.		1
207	The Prolyl Peptidyl Isomerase Pin1 as a Potential Therapeutic Target in Atherosclerosis. Clinical & Experimental Pharmacology, 2012, 2, .	0.3	1
208	The Growing Promiscuity of G Protein Coupled Receptors. Clinical & Experimental Pharmacology, 2012, 02, .	0.3	1
209	UNDEREXPRESSION OF THE 43 KDA INOSITOL POLY-PHOSPHATE 5-PHOSPHATASE IS ASSOCIATED WITH CELLULAR TRANSFORMATION. Biochemical Society Transactions, 1996, 24, 624S-624S.	1.6	0
210	Calcific Aortic Valve Disease and Hypertension. Current Hypertension Reviews, 2008, 4, 107-113.	0.5	0
211	Fixedâ€dose statins with no lipid targets: a new paradigm of dosing?. Journal of Pharmacy Practice and Research, 2014, 44, 64-65.	0.5	0
212	Lipid: Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes. Contemporary Diabetes, 2014, , 215-229.	0.0	0
213	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. Contemporary Diabetes, 2014, , 435-453.	0.0	0
214	Multidisciplinary involvement in completion of a hospital medication management plan in a tertiary hospital in australia. Journal of Pharmacy Practice and Research, 2016, 46, 192-194.	0.5	0
215	Cover Image, Volume 40, Issue 6. Medicinal Research Reviews, 2020, 40, ii.	5.0	0